Global Thyroid Disorder Therapy Market

Thyroid Disorder Therapy Comprehensive Study by Drug Type (Kinase Inhibitors, Anthracyclines, Beta-Blockers, Others), Disease Type (Hypothyroidism, Hyperthyroidism, Goiter, Hashimoto Disease, Others), Route of Administration (Oral, Intravenous, Rectal, Intramuscular, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Treatment Method (Medication, Radioiodine therapy, Surgery, Other Therapies) Players and Region - Global Market Outlook to 2030

Thyroid Disorder Therapy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Thyroid Disorder Therapy
Thyroid disorders may lead to elevated or decreased levels of metabolic hormones, leading to medical conditions such as hypothyroidism and hyperthyroidism. Thyroid can be caused by iodine deficiency and autoimmune disease. Iodine deficiency is a major factor that may lead to thyroid disorder. Technological advancement in thyroid disorder therapy is also driving growth of the thyroid disorder therapy market during the forecast period. Radioactive iodine (I-131) has been used to treat over-active thyroid disorders (hyperthyroidism). It is an effective method of treatment. It is now being used more often as a first-line treatment rather than surgery, which reduces the amount of thyroxin and size of gland. The thyroid disorder therapy market is poised for expansion in the foreseeable future. Increasing disease prevalence, growing awareness, and advancements in treatment options are expected to be the key drivers of this market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The Thyroid Disorder Therapy market is on an upward trajectory, driven by an aging population and rising demand for comfortable recovery at home. This translates to a fierce competition among manufacturers. Here's a breakdown of the competitive landscape in the Thyroid Disorder Therapy. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Thyroid Disorder Therapy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Amgen Inc. (United States), AstraZeneca (United Kingdom), Bayer AG (Germany), Curium Pharma (Netherland), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc (United Kingdom), PIUR IMAGING (Austria), Otsuka Holdings Co., Ltd. (Japan), Sanofi (France) and Shionogi & Co., Ltd. (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sun Pharmaceutical Industries Ltd. (India), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Takeda Pharmaceutical Company Limited (Japan) and Abbott (United States).

Segmentation Overview
AMA Research has segmented the market of Global Thyroid Disorder Therapy market by and Region.



On the basis of geography, the market of Thyroid Disorder Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. Kinase Inhibitors will boost the Thyroid Disorder Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Type, the sub-segment i.e. Hypothyroidism will boost the Thyroid Disorder Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Thyroid Disorder Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Thyroid Disorder Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Method, the sub-segment i.e. Medication will boost the Thyroid Disorder Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Personalized Therapy and Targeted therapies

Market Growth Drivers:
Increased Prevalence of Thyroid Disorder

Challenges:
Side Effects of Some of the Drugs Used for Treatment of the Disease

Restraints:
Limited access to healthcare services

Opportunities:
Telemedicine and Remote monitoring and Development of Effective Combination Drug Therapies to Treat Thyroid Gland Disorders

Market Leaders and their expansionary development strategies
In October 2023, Curium and PIUR IMAGING announced a strategic partnership to advance thyroid diagnostics. The partnership agreement, PIUR IMAGING will provide and continuously develop the hardware and software solution, with Curium responsible for the exclusive distribution of the product in nuclear medicine.
In October 2023, Amgen announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for Medical Oncology, taking place from results from Amgen-sponsored and collaborative studies, including two late-breaking oral presentations, will feature data in a range of tough-to-treat cancers.


Key Target Audience
Research & Development Organization, Government & Regulatory Bodies, Market Research & Consultancy Firm, Potential Investors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Drug Type
  • Kinase Inhibitors
  • Anthracyclines
  • Beta-Blockers
  • Others

By Disease Type
  • Hypothyroidism
  • Hyperthyroidism
  • Goiter
  • Hashimoto Disease
  • Others

By Route of Administration
  • Oral
  • Intravenous
  • Rectal
  • Intramuscular
  • Others

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Treatment Method
  • Medication
  • Radioiodine therapy
  • Surgery
  • Other Therapies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Thyroid Disorder
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of Some of the Drugs Used for Treatment of the Disease
    • 3.4. Market Trends
      • 3.4.1. Personalized Therapy and Targeted therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Thyroid Disorder Therapy, by Drug Type, Disease Type, Route of Administration, Distribution Channel, Treatment Method and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Thyroid Disorder Therapy (Value)
      • 5.2.1. Global Thyroid Disorder Therapy by: Drug Type (Value)
        • 5.2.1.1. Kinase Inhibitors
        • 5.2.1.2. Anthracyclines
        • 5.2.1.3. Beta-Blockers
        • 5.2.1.4. Others
      • 5.2.2. Global Thyroid Disorder Therapy by: Disease Type (Value)
        • 5.2.2.1. Hypothyroidism
        • 5.2.2.2. Hyperthyroidism
        • 5.2.2.3. Goiter
        • 5.2.2.4. Hashimoto Disease
        • 5.2.2.5. Others
      • 5.2.3. Global Thyroid Disorder Therapy by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Intravenous
        • 5.2.3.3. Rectal
        • 5.2.3.4. Intramuscular
        • 5.2.3.5. Others
      • 5.2.4. Global Thyroid Disorder Therapy by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Retail Pharmacy
        • 5.2.4.3. Online Pharmacy
        • 5.2.4.4. Others
      • 5.2.5. Global Thyroid Disorder Therapy by: Treatment Method (Value)
        • 5.2.5.1. Medication
        • 5.2.5.2. Radioiodine therapy
        • 5.2.5.3. Surgery
        • 5.2.5.4. Other Therapies
      • 5.2.6. Global Thyroid Disorder Therapy Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Thyroid Disorder Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Curium Pharma (Netherland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. PIUR IMAGING (Austria)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Otsuka Holdings Co., Ltd. (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Shionogi & Co., Ltd. (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Thyroid Disorder Therapy Sale, by Drug Type, Disease Type, Route of Administration, Distribution Channel, Treatment Method and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Thyroid Disorder Therapy (Value)
      • 7.2.1. Global Thyroid Disorder Therapy by: Drug Type (Value)
        • 7.2.1.1. Kinase Inhibitors
        • 7.2.1.2. Anthracyclines
        • 7.2.1.3. Beta-Blockers
        • 7.2.1.4. Others
      • 7.2.2. Global Thyroid Disorder Therapy by: Disease Type (Value)
        • 7.2.2.1. Hypothyroidism
        • 7.2.2.2. Hyperthyroidism
        • 7.2.2.3. Goiter
        • 7.2.2.4. Hashimoto Disease
        • 7.2.2.5. Others
      • 7.2.3. Global Thyroid Disorder Therapy by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Intravenous
        • 7.2.3.3. Rectal
        • 7.2.3.4. Intramuscular
        • 7.2.3.5. Others
      • 7.2.4. Global Thyroid Disorder Therapy by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Retail Pharmacy
        • 7.2.4.3. Online Pharmacy
        • 7.2.4.4. Others
      • 7.2.5. Global Thyroid Disorder Therapy by: Treatment Method (Value)
        • 7.2.5.1. Medication
        • 7.2.5.2. Radioiodine therapy
        • 7.2.5.3. Surgery
        • 7.2.5.4. Other Therapies
      • 7.2.6. Global Thyroid Disorder Therapy Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Thyroid Disorder Therapy: by Drug Type(USD Million)
  • Table 2. Thyroid Disorder Therapy Kinase Inhibitors , by Region USD Million (2018-2023)
  • Table 3. Thyroid Disorder Therapy Anthracyclines , by Region USD Million (2018-2023)
  • Table 4. Thyroid Disorder Therapy Beta-Blockers , by Region USD Million (2018-2023)
  • Table 5. Thyroid Disorder Therapy Others , by Region USD Million (2018-2023)
  • Table 6. Thyroid Disorder Therapy: by Disease Type(USD Million)
  • Table 7. Thyroid Disorder Therapy Hypothyroidism , by Region USD Million (2018-2023)
  • Table 8. Thyroid Disorder Therapy Hyperthyroidism , by Region USD Million (2018-2023)
  • Table 9. Thyroid Disorder Therapy Goiter , by Region USD Million (2018-2023)
  • Table 10. Thyroid Disorder Therapy Hashimoto Disease , by Region USD Million (2018-2023)
  • Table 11. Thyroid Disorder Therapy Others , by Region USD Million (2018-2023)
  • Table 12. Thyroid Disorder Therapy: by Route of Administration(USD Million)
  • Table 13. Thyroid Disorder Therapy Oral , by Region USD Million (2018-2023)
  • Table 14. Thyroid Disorder Therapy Intravenous , by Region USD Million (2018-2023)
  • Table 15. Thyroid Disorder Therapy Rectal , by Region USD Million (2018-2023)
  • Table 16. Thyroid Disorder Therapy Intramuscular , by Region USD Million (2018-2023)
  • Table 17. Thyroid Disorder Therapy Others , by Region USD Million (2018-2023)
  • Table 18. Thyroid Disorder Therapy: by Distribution Channel(USD Million)
  • Table 19. Thyroid Disorder Therapy Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 20. Thyroid Disorder Therapy Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 21. Thyroid Disorder Therapy Online Pharmacy , by Region USD Million (2018-2023)
  • Table 22. Thyroid Disorder Therapy Others , by Region USD Million (2018-2023)
  • Table 23. Thyroid Disorder Therapy: by Treatment Method(USD Million)
  • Table 24. Thyroid Disorder Therapy Medication , by Region USD Million (2018-2023)
  • Table 25. Thyroid Disorder Therapy Radioiodine therapy , by Region USD Million (2018-2023)
  • Table 26. Thyroid Disorder Therapy Surgery , by Region USD Million (2018-2023)
  • Table 27. Thyroid Disorder Therapy Other Therapies , by Region USD Million (2018-2023)
  • Table 28. South America Thyroid Disorder Therapy, by Country USD Million (2018-2023)
  • Table 29. South America Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 30. South America Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 31. South America Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 32. South America Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 33. South America Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 34. Brazil Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 35. Brazil Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 36. Brazil Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 37. Brazil Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 38. Brazil Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 39. Argentina Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 40. Argentina Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 41. Argentina Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 42. Argentina Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 43. Argentina Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 44. Rest of South America Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 45. Rest of South America Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 46. Rest of South America Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 47. Rest of South America Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 48. Rest of South America Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 49. Asia Pacific Thyroid Disorder Therapy, by Country USD Million (2018-2023)
  • Table 50. Asia Pacific Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 51. Asia Pacific Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 52. Asia Pacific Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 53. Asia Pacific Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 54. Asia Pacific Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 55. China Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 56. China Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 57. China Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 58. China Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 59. China Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 60. Japan Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 61. Japan Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 62. Japan Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 63. Japan Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 64. Japan Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 65. India Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 66. India Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 67. India Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 68. India Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 69. India Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 70. South Korea Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 71. South Korea Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 72. South Korea Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 73. South Korea Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 74. South Korea Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 75. Taiwan Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 76. Taiwan Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 77. Taiwan Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 78. Taiwan Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 79. Taiwan Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 80. Australia Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 81. Australia Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 82. Australia Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 83. Australia Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 84. Australia Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 88. Rest of Asia-Pacific Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 89. Rest of Asia-Pacific Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 90. Europe Thyroid Disorder Therapy, by Country USD Million (2018-2023)
  • Table 91. Europe Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 92. Europe Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 93. Europe Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 94. Europe Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 95. Europe Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 96. Germany Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 97. Germany Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 98. Germany Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 99. Germany Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 100. Germany Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 101. France Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 102. France Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 103. France Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 104. France Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 105. France Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 106. Italy Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 107. Italy Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 108. Italy Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 109. Italy Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 110. Italy Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 111. United Kingdom Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 112. United Kingdom Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 113. United Kingdom Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 114. United Kingdom Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 115. United Kingdom Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 116. Netherlands Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 117. Netherlands Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 118. Netherlands Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 119. Netherlands Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 120. Netherlands Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 121. Rest of Europe Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 122. Rest of Europe Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 123. Rest of Europe Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 124. Rest of Europe Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 125. Rest of Europe Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 126. MEA Thyroid Disorder Therapy, by Country USD Million (2018-2023)
  • Table 127. MEA Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 128. MEA Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 129. MEA Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 130. MEA Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 131. MEA Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 132. Middle East Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 133. Middle East Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 134. Middle East Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 135. Middle East Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 136. Middle East Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 137. Africa Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 138. Africa Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 139. Africa Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 140. Africa Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 141. Africa Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 142. North America Thyroid Disorder Therapy, by Country USD Million (2018-2023)
  • Table 143. North America Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 144. North America Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 145. North America Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 146. North America Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 147. North America Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 148. United States Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 149. United States Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 150. United States Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 151. United States Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 152. United States Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 153. Canada Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 154. Canada Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 155. Canada Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 156. Canada Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 157. Canada Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 158. Mexico Thyroid Disorder Therapy, by Drug Type USD Million (2018-2023)
  • Table 159. Mexico Thyroid Disorder Therapy, by Disease Type USD Million (2018-2023)
  • Table 160. Mexico Thyroid Disorder Therapy, by Route of Administration USD Million (2018-2023)
  • Table 161. Mexico Thyroid Disorder Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 162. Mexico Thyroid Disorder Therapy, by Treatment Method USD Million (2018-2023)
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Thyroid Disorder Therapy: by Drug Type(USD Million)
  • Table 174. Thyroid Disorder Therapy Kinase Inhibitors , by Region USD Million (2025-2030)
  • Table 175. Thyroid Disorder Therapy Anthracyclines , by Region USD Million (2025-2030)
  • Table 176. Thyroid Disorder Therapy Beta-Blockers , by Region USD Million (2025-2030)
  • Table 177. Thyroid Disorder Therapy Others , by Region USD Million (2025-2030)
  • Table 178. Thyroid Disorder Therapy: by Disease Type(USD Million)
  • Table 179. Thyroid Disorder Therapy Hypothyroidism , by Region USD Million (2025-2030)
  • Table 180. Thyroid Disorder Therapy Hyperthyroidism , by Region USD Million (2025-2030)
  • Table 181. Thyroid Disorder Therapy Goiter , by Region USD Million (2025-2030)
  • Table 182. Thyroid Disorder Therapy Hashimoto Disease , by Region USD Million (2025-2030)
  • Table 183. Thyroid Disorder Therapy Others , by Region USD Million (2025-2030)
  • Table 184. Thyroid Disorder Therapy: by Route of Administration(USD Million)
  • Table 185. Thyroid Disorder Therapy Oral , by Region USD Million (2025-2030)
  • Table 186. Thyroid Disorder Therapy Intravenous , by Region USD Million (2025-2030)
  • Table 187. Thyroid Disorder Therapy Rectal , by Region USD Million (2025-2030)
  • Table 188. Thyroid Disorder Therapy Intramuscular , by Region USD Million (2025-2030)
  • Table 189. Thyroid Disorder Therapy Others , by Region USD Million (2025-2030)
  • Table 190. Thyroid Disorder Therapy: by Distribution Channel(USD Million)
  • Table 191. Thyroid Disorder Therapy Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 192. Thyroid Disorder Therapy Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 193. Thyroid Disorder Therapy Online Pharmacy , by Region USD Million (2025-2030)
  • Table 194. Thyroid Disorder Therapy Others , by Region USD Million (2025-2030)
  • Table 195. Thyroid Disorder Therapy: by Treatment Method(USD Million)
  • Table 196. Thyroid Disorder Therapy Medication , by Region USD Million (2025-2030)
  • Table 197. Thyroid Disorder Therapy Radioiodine therapy , by Region USD Million (2025-2030)
  • Table 198. Thyroid Disorder Therapy Surgery , by Region USD Million (2025-2030)
  • Table 199. Thyroid Disorder Therapy Other Therapies , by Region USD Million (2025-2030)
  • Table 200. South America Thyroid Disorder Therapy, by Country USD Million (2025-2030)
  • Table 201. South America Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 202. South America Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 203. South America Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 204. South America Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 205. South America Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 206. Brazil Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 207. Brazil Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 208. Brazil Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 209. Brazil Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 210. Brazil Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 211. Argentina Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 212. Argentina Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 213. Argentina Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 214. Argentina Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 215. Argentina Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 216. Rest of South America Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 217. Rest of South America Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 218. Rest of South America Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 219. Rest of South America Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 220. Rest of South America Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 221. Asia Pacific Thyroid Disorder Therapy, by Country USD Million (2025-2030)
  • Table 222. Asia Pacific Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 223. Asia Pacific Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 224. Asia Pacific Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 225. Asia Pacific Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 226. Asia Pacific Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 227. China Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 228. China Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 229. China Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 230. China Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 231. China Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 232. Japan Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 233. Japan Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 234. Japan Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 235. Japan Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 236. Japan Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 237. India Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 238. India Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 239. India Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 240. India Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 241. India Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 242. South Korea Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 243. South Korea Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 244. South Korea Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 245. South Korea Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 246. South Korea Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 247. Taiwan Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 248. Taiwan Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 249. Taiwan Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 250. Taiwan Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 251. Taiwan Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 252. Australia Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 253. Australia Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 254. Australia Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 255. Australia Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 256. Australia Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 257. Rest of Asia-Pacific Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 258. Rest of Asia-Pacific Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 259. Rest of Asia-Pacific Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 260. Rest of Asia-Pacific Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 261. Rest of Asia-Pacific Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 262. Europe Thyroid Disorder Therapy, by Country USD Million (2025-2030)
  • Table 263. Europe Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 264. Europe Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 265. Europe Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 266. Europe Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 267. Europe Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 268. Germany Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 269. Germany Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 270. Germany Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 271. Germany Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 272. Germany Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 273. France Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 274. France Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 275. France Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 276. France Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 277. France Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 278. Italy Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 279. Italy Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 280. Italy Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 281. Italy Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 282. Italy Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 283. United Kingdom Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 284. United Kingdom Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 285. United Kingdom Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 286. United Kingdom Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 287. United Kingdom Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 288. Netherlands Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 289. Netherlands Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 290. Netherlands Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 291. Netherlands Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 292. Netherlands Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 293. Rest of Europe Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 294. Rest of Europe Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 295. Rest of Europe Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 296. Rest of Europe Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 297. Rest of Europe Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 298. MEA Thyroid Disorder Therapy, by Country USD Million (2025-2030)
  • Table 299. MEA Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 300. MEA Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 301. MEA Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 302. MEA Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 303. MEA Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 304. Middle East Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 305. Middle East Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 306. Middle East Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 307. Middle East Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 308. Middle East Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 309. Africa Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 310. Africa Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 311. Africa Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 312. Africa Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 313. Africa Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 314. North America Thyroid Disorder Therapy, by Country USD Million (2025-2030)
  • Table 315. North America Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 316. North America Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 317. North America Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 318. North America Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 319. North America Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 320. United States Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 321. United States Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 322. United States Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 323. United States Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 324. United States Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 325. Canada Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 326. Canada Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 327. Canada Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 328. Canada Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 329. Canada Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 330. Mexico Thyroid Disorder Therapy, by Drug Type USD Million (2025-2030)
  • Table 331. Mexico Thyroid Disorder Therapy, by Disease Type USD Million (2025-2030)
  • Table 332. Mexico Thyroid Disorder Therapy, by Route of Administration USD Million (2025-2030)
  • Table 333. Mexico Thyroid Disorder Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 334. Mexico Thyroid Disorder Therapy, by Treatment Method USD Million (2025-2030)
  • Table 335. Research Programs/Design for This Report
  • Table 336. Key Data Information from Secondary Sources
  • Table 337. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Thyroid Disorder Therapy: by Drug Type USD Million (2018-2023)
  • Figure 5. Global Thyroid Disorder Therapy: by Disease Type USD Million (2018-2023)
  • Figure 6. Global Thyroid Disorder Therapy: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Thyroid Disorder Therapy: by Distribution Channel USD Million (2018-2023)
  • Figure 8. Global Thyroid Disorder Therapy: by Treatment Method USD Million (2018-2023)
  • Figure 9. South America Thyroid Disorder Therapy Share (%), by Country
  • Figure 10. Asia Pacific Thyroid Disorder Therapy Share (%), by Country
  • Figure 11. Europe Thyroid Disorder Therapy Share (%), by Country
  • Figure 12. MEA Thyroid Disorder Therapy Share (%), by Country
  • Figure 13. North America Thyroid Disorder Therapy Share (%), by Country
  • Figure 14. Global Thyroid Disorder Therapy share by Players 2023 (%)
  • Figure 15. Global Thyroid Disorder Therapy share by Players (Top 3) 2023(%)
  • Figure 16. Global Thyroid Disorder Therapy share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 20. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 22. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 24. Curium Pharma (Netherland) Revenue, Net Income and Gross profit
  • Figure 25. Curium Pharma (Netherland) Revenue: by Geography 2023
  • Figure 26. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 28. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 30. PIUR IMAGING (Austria) Revenue, Net Income and Gross profit
  • Figure 31. PIUR IMAGING (Austria) Revenue: by Geography 2023
  • Figure 32. Otsuka Holdings Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Otsuka Holdings Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 34. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 35. Sanofi (France) Revenue: by Geography 2023
  • Figure 36. Shionogi & Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Shionogi & Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 38. Global Thyroid Disorder Therapy: by Drug Type USD Million (2025-2030)
  • Figure 39. Global Thyroid Disorder Therapy: by Disease Type USD Million (2025-2030)
  • Figure 40. Global Thyroid Disorder Therapy: by Route of Administration USD Million (2025-2030)
  • Figure 41. Global Thyroid Disorder Therapy: by Distribution Channel USD Million (2025-2030)
  • Figure 42. Global Thyroid Disorder Therapy: by Treatment Method USD Million (2025-2030)
  • Figure 43. South America Thyroid Disorder Therapy Share (%), by Country
  • Figure 44. Asia Pacific Thyroid Disorder Therapy Share (%), by Country
  • Figure 45. Europe Thyroid Disorder Therapy Share (%), by Country
  • Figure 46. MEA Thyroid Disorder Therapy Share (%), by Country
  • Figure 47. North America Thyroid Disorder Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Amgen Inc. (United States)
  • AstraZeneca (United Kingdom)
  • Bayer AG (Germany)
  • Curium Pharma (Netherland)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • GlaxoSmithKline plc (United Kingdom)
  • PIUR IMAGING (Austria)
  • Otsuka Holdings Co., Ltd. (Japan)
  • Sanofi (France)
  • Shionogi & Co., Ltd. (Japan)
Additional players considered in the study are as follows:
Sun Pharmaceutical Industries Ltd. (India) , Pfizer Inc. (United States) , Teva Pharmaceutical Industries Ltd. (Israel) , Takeda Pharmaceutical Company Limited (Japan) , Abbott (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 250 Pages 60 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Thyroid Disorder Therapy Market Quantitative research analysis
Global Thyroid Disorder Therapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Amgen Inc. (United States), AstraZeneca (United Kingdom), Bayer AG (Germany), Curium Pharma (Netherland), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc (United Kingdom), PIUR IMAGING (Austria), Otsuka Holdings Co., Ltd. (Japan), Sanofi (France) and Shionogi & Co., Ltd. (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Personalized Therapy and Targeted therapies" is seen as one of major influencing trends for Thyroid Disorder Therapy Market during projected period 2023-2030.
The Thyroid Disorder Therapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Thyroid Disorder Therapy Market Report?

Have a Query? Click Here

Other Related Reports

Depression Therapeutics- Comprehensive Study by Indication Type (Major depressive disorder (MDD), Bipolar disorder, Dysthymic disorder, Postpartum depression, Seasonal affective disorder (SAD), Preme...
$ 3800
Ischemic stroke Comprehensive Study by Surgery Type (Carotid Endarterectomy, Angioplasty, Endovascular Mechanical Thrombectomy, Others), Treatment Type (Tissue Plasminogen Activator, Anticoagulant, A...
$ 3800
Cardiovascular Application Comprehensive Study by Type (Diagnostic and Monitoring Devices, (Electrocardiogram, Holter Monitors, Event Monitors, Others), Interventional Devices, (Coronary Stents, Cath...
$ 3800
Membranous Nephropathy Comprehensive Study by Type (Primary Membranous Nephropathy (Idiopathic), Secondary Membranous Nephropathy), Age Group (Children, Adults), Treatment Type (Biologics, Pharmaceut...
$ 3800
Malocclusion Comprehensive Study by Type (Overcrowding, Spacing, Openbite, Overjet, Overbite, Underbite, Crossbite, Diastema, Impacted Tooth, Missing Tooth), Age Group (Children, Adults), Treatment T...
$ 3800
Orphan Diseases Comprehensive Study by Disease Type (Oncology, Allergic and Immunologic Disorders, Cardiac and Vascular Conditions, Infectious Diseases, Neurologic Conditions, Skin and Soft Tissue Co...
$ 3800